Duchenne muscular dystrophy (DMD) is a lethal disease caused by the lack of the cytoskeletal protein dystrophin. Altered calcium homoeostasis and increased calcium concentrations in dystrophic fibres may be responsible for the degeneration of muscle occurring in DMD. In the present study, we used subsarcolemmaland mitochondrial-targeted aequorin to study the effect of the antiapoptotic Bcl-2 protein overexpression on carbachol-induced near-plasma membrane and mitochondrial calcium responses in myotubes derived from control C57 and dystrophic (mdx) mice. We show that Bcl-2 overexpression decreases subsarcolemmal and mitochondrial calcium overload that occurs during activation of nicotinic acetylcholine receptors in dystrophic myotubes. Moreover, our results suggest that overexpressed Bcl-2 protein may prevent near-plasma membrane and mitochondrial calcium overload by inhibiting IP 3 Rs (inositol 1,4,5-trisphosphate receptors), which we have shown previously to be involved in abnormal calcium homoeostasis in dystrophic myotubes. Most likely as a consequence, the inhibition of IP 3 R function by Bcl-2 also inhibits calcium-dependent apoptosis in these cells.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease that affects approx. 1 in 3500 males and which results in progressive muscle degeneration [1] . DMD ultimately leads to premature death by respiratory or cardiac failure during the third decade and is caused by the absence of dystrophin, a 427 kDa protein localized under the plasma membrane [2] . Numerous studies have shown that the absence of dystrophin in DMD impairs the stability of the plasma membrane, resulting in a greater fragility towards mechanical stress and increased permeability to calcium (Ca 2+ ) [3] . Indeed, it has been proposed that an alteration of Ca 2+ homoeostasis might be responsible for the muscle degeneration that occurs in muscle fibres from DMD patients or in those of the mouse model of DMD, the mdx mouse [4] . Moreover, elevations of basal Ca 2+ concentration in myotubes and skeletalmuscle fibres from DMD patients or mdx mice have been reported [5] .
Long-term elevation of cytosolic Ca 2+ is linked to apoptosis [6] and mitochondrial Ca 2+ overload activates the PTP (permeability transition pore) leading to cell death [7] . Because Ca 2+ overload occurs in dystrophic myotubes and fibres, the involvement of apoptosis in these cells has been studied but is still a matter of debate. Indeed, it remains unclear if apoptosis causes or is secondary to muscle degradation [8, 9] . Thus some groups have suggested that necrosis only occurs in dystrophin-lacking cells [10] . Other groups have shown that apoptosis occurs in dystrophic cells [11] and finally that both apoptosis and necrosis occur in DMD [12] . Therefore apoptosis, linked to necrosis or not, could be responsible for the muscle degeneration that occurs in mdx cells and DMD patients [13] .
Apoptosis is a highly regulated process and numerous studies have shown that the Bcl-2 protein, which belongs to the Bcl-2 family, could regulate apoptosis by modulating the release of mitochondrial apoptogenic factors like cytochrome c or apoptosis-inducing factor that activate proteases such as caspases [14] . Even if the exact role of the Bcl-2 protein is still unclear and debated [15] , Bcl-2 could act by decreasing Ca 2+ concentration in the SR (sarcoplasmic reticulum) [16] and other cellular compartments such as mitochondria [17] . Recent studies have postulated that Bcl-2 could interact directly with IP 3 R (inositol 1,4,5-trisphosphate receptor) [18, 19] . This receptor is known to be overexpressed in dystrophic myotubes [20] . We have shown recently that IP 3 R is involved in increased CCh (carbachol)-induced near-plasma membrane Ca 2+ responses in dystrophic myotubes [21] . However, at present, the effect of Bcl-2 overexpression on both near-plasma membrane and mitochondrial Ca 2+ transients has not been studied in dystrophic myotubes.
In the present paper, we have studied the effect of overexpression of the anti-apoptotic protein Bcl-2 on CCh-induced Ca 2+ responses in subcellular compartments. We have also investigated the effect of Bcl-2 overexpression on cell survival and apoptosis of myotubes derived from control C57 and dystrophic mice. We show that Bcl-2 overexpression decreases near-plasma membrane and mitochondrial CCh-induced Ca 2+ transients in dystrophic myotubes. We also show that Bcl-2 overexpression prevents Ca 2+ -dependent apoptosis in dystrophic myotubes and that the beneficial effect of Bcl-2 overexpression may be mediated by a direct Bcl-2-dependent IP 3 R inhibition.
EXPERIMENTAL

Cell culture
Cultures of purified myoblasts were prepared in Petri dishes (Falcon, Becton Dickinson) and maintained at 37
• C in a watersaturated atmosphere of 95 % air/5 % CO 2 . They were obtained as described previously [21] . 
Confocal microscopy
Mdx and control C57 myotubes were grown in plastic culture dishes and transfected with pcDNA3 expression vector containing cDNA encoding Bcl-2. The immunolabelled samples were examined by confocal laser scanning microscopy using a Bio-Rad MRC 1024 ES (Bio-Rad, Hemel Hempstead, U.K.) equipped with an argon-krypton gas laser, 3-4 days after differentiation. The Alexa Fluor fluorochrome was excited with the 488 nm green line and the emission was collected at 520 nm. Mitotracker was excited with the 550 nm red line and the emission was collected at 580 nm. Data were acquired using an inverted microscope (Olympus IX70) and processed with the LaserSharp software (version 3.0; BioRad).
Western blot
Bcl-2 protein content of control C57 and mdx myotubes was determined using Western blotting. Equal amounts of protein extracted were loaded on to SDS/12 % PAGE. The relative content of muscle protein in the samples was adjusted according to the actin (antibody dilution 1:500; A2172; Sigma) band. Proteins were transferred to nitrocellulose membranes (Bio-Rad). The Bcl-2 protein was detected using the Bcl-2-specific antibody at a dilution of 1:2500. Subsequently, alkaline phosphatase-conjugated goat anti-mouse (170-6520; Bio-Rad) was used at a dilution of 1:1000. Specific signals were detected with the ECF (enhanced fluorescence) Western blotting detection reagent (Amersham Biosciences).
Intracellular calcium measurements
After 3-4 days of differentiation, Ca 2+ concentration was determined in a population of myotubes as described previously [21] . Briefly, aequorins were reconstituted in a PSS containing 5 µM coelenterazine (Calbiochem) for 1 h before the experiment. Particular conditions are needed for the subsarcolemmal-targeted aequorin because the removal of intracellular Ca 2+ is required for the complete aequorin reconstitution [26] . Thus SNAP-25-aequorin was reconstituted in a Ca 2+ -free PSS containing 0.1 mM EGTA in order to decrease the [Ca 2+ ] within the cell. Mitochondrial-targeted aequorin was reconstituted in 1.2 mM Ca 2+ . Cells were perfused at a rate of 1 ml/min in a custom made 0.5 ml chamber thermostatically maintained at 37
• C (MecaTest, Geneva, Switzerland). Emitted luminescence was detected at 466 nm with a photomultiplier apparatus (EMI 9789A; Electron Tubes, U.K.) and recorded every 1 s using a computer photon-counting board (EMI C660) as described previously [27] . The relationship between recorded emitted light and [Ca 2+ ] was calculated using a previously described equation [28] . Total light output was obtained by exposing cells to 10 mM CaCl 2 after permeabilization with 100 µM digitonin to consume all the aequorin.
Survival assay and apoptosis
The enzymatic colorimetric measurement of the phosphatase acid activity was used to determine the effect of Bcl-2 overexpression on the survival of the myotubes. Myotubes were cultured in 24-well plates coated with collagen. Briefly, after 3-4 days of differentiation, cells were washed twice for 5 min with 500 µl of PBS (0.2 g/l KCl, 0.2 g/l KH 2 PO 4 , 8 g/l NaCl and 1.15 g/l NaH 2 PO 4 , pH 7.2). Then 250 µl of substrate solution containing citrate buffer aqueous solution (0.1 M, pH 5.5), 0.1 % Triton X-100 and 1 mg/ml p-nitrophenyl phosphate substrate was added to each well for 90 min. The reaction was stopped by adding 25 µl of 1 M NaOH. Absorbance was measured at 405 nm.
The APO percentage apoptosis assay (Biocolor, Newtownabbey, U.K.) was used to assess the effect of Bcl-2 overexpression on apoptosis. Cellular dye uptake was analysed according to the manufacturer's method modified for our myotubes that were cultured in 24-well plates coated with collagen. Briefly, after a 90 min incubation at 37
• C with APODye reagent (dilution 1:20), cells were washed with PSS to remove extracellular dye. Subsequently, APO dye release reagent was applied for 10 min and absorbance of the released dye was measured at 550 nm with a plate reader (Fluostar Galaxy; BMG Labtechnologies).
Data analysis
Data analysis was performed using the software GraphPad Prism 4 (GraphPad Software, San Diego, CA, U.S.A.) and Matlab 7 SP1 (The MathWorks, Natick, MA, U.S.A.). Results are expressed as means + − S.E.M. Statistical significance of differences between the values was assessed with the unpaired Student's t test and oneway ANOVA followed by Dunnett post-hoc test when necessary. P values 0.05 were considered significant.
RESULTS
Bcl-2 localization and overexpression
In order to investigate the localization of the Bcl-2 protein, myoblasts were transfected with cDNA encoding Bcl-2. Localization of Bcl-2 was assessed using immunochemistry and confocal imaging. Figure 1 shows representative confocal sections of dystrophic myotubes after 3 days of differentiation. The green fluorescence alone corresponds to overexpressed Bcl-2 protein (Figure 1A) , as no fluorescence was detected in non-transfected myotubes (results not shown). Overexpressed Bcl-2 protein appears to be located on membranes which could be SR membranes and also in the perinuclear area. Double staining of Bcl-2 protein and mitochondria (with mitotracker, red fluorescence) indicates that overexpressed Bcl-2 proteins were located in part in mitochondria (yellow fluorescence, Figure 1B) . Similar results were obtained with control C57 myotubes (results not shown). Bcl-2 overexpression was confirmed by Western-blot analysis of both control C57 and mdx myotubes ( Figure 1C ). Indeed, Bcl-2 protein was only detected in transfected myotubes. Moreover, results shown in Figure 1 (C) indicate that Bcl-2 was similarly expressed in both cell types. [26] . Stimulation of myotubes with CCh triggered near-plasma membrane Ca 2+ increases with average amplitudes of 1.10 + − 0.11 and 5.04 + − 0.81 µM for control C57 and dystrophic myotubes respectively. Bcl-2 overexpression did not affect significantly the CCh-induced near-plasma membrane Ca 2+ increases in control C57 myotubes but decreased this response in dystrophic myotubes approx. 2-fold (to 2.35 + − 0.35 µM; Figure 2 ). These results demonstrate that the CCh-induced Ca 2+ increase is five times higher in dystrophic myotubes as compared with control C57 cells. These results also show that Bcl-2 overexpression decreases CCh-induced nearplasma membrane Ca 2+ increases only in dystrophic myotubes. Thus Bcl-2 overexpression appears to correct exaggerated nearplasma membrane Ca 2+ transients that occurred during stimulation of nAChRs in dystrophic myotubes. We have previously shown that the increased CCh-induced Ca 2+ response in dystrophic myotubes involves Ca 2+ release through IP 3 Rs [21] , which have been shown to be overexpressed in dystrophic myotubes [20] . As Bcl-2 protein has been shown to interact directly with IP 3 R and to inhibit its opening [18] , we next investigated the effect of potent IP 3 R inhibitors on CCh-induced near-plasma membrane Ca 2+ increases in dystrophic myotubes. As shown in Figure 3 , incubation of dystrophic myotubes that overexpress Bcl-2 with either 2-APB (2-aminoethoxydiphenyl borate; 75 µM) [29] or xestospongin D (0.1 µM) [30] Figure 3C ). In contrast, in dystrophic myotubes that do not ; n 8; *** corresponds to a significant inhibition (P < 0.001) using one-way ANOVA followed by a Dunnett post-hoc test when compared with the control bar, e.g. 1.2 mM Ca 2+ , 100 µM CCh, no Bcl-2 overexpression.
overexpress Bcl-2, the two IP 3 R inhibitors have been shown to strongly reduce CCh-induced Ca 2+ responses [21] . Altogether, these results suggest that Bcl-2, when overexpressed in dystrophic myotubes, may reduce CCh-induced Ca 2+ responses by inhibiting the IP 3 R, as shown in other cell types [18] .
To confirm that Bcl-2 could act by inhibiting IP 3 R, we used saponin-permeabilized dystrophic myotubes perfused with 50 µM IP 3 . As shown in Figure 4 , perfusion with this second messenger induced a subsarcolemmal Ca 2+ increase with a maximal amplitude of 2.10 + − 0.14 µM, whereas Ca 2+ readdition alone triggered a maximal Ca 2+ transient of 0.92 + − 0.13 µM. In myotubes ] values + − S.E.M.; n 6; ns, not significant (P > 0.05); ** corresponds to a significant inhibition (0.01 < P < 0.001) using unpaired Student's t test.
overexpressing Bcl-2, the IP 3 -induced Ca 2+ response was significantly decreased when compared with myotubes not overexpressing the anti-apoptotic protein (from 2.10 + − 0.14 to 1.62 + − 0.09 µM). Perfusion with the L-enantiomer of IP 3 (50 µM), known to have very little affinity for IP 3 R, did not significantly change the subsarcolemmal Ca 2+ response when compared with Ca 2+ readdition (1.08 + − 0.07 and 0.92 + − 0.13 µM respectively). Thus Ca 2+ transients induced by both CCh, which triggers an IP 3 -dependent Ca 2+ response [21] , and IP 3 , which acts directly on IP 3 R, are inhibited by Bcl-2 overexpression. However, Bcl-2 overexpression has also been shown to affect SR Ca 2+ content in some cases [16] . To test this hypothesis, we investigated the effect of caffeine (20 mM), an activator of the ryanodine receptor [31] ] values + − S.E.M. ns, not significant (P > 0.05); * and ** correspond to a significant inhibition (P < 0.05 and 0.01 < P < 0.001 respectively) using unpaired Student's t test.
in dystrophic myotubes, thus leading to a reduced near-plasma membrane Ca 2+ transient during activation with CCh.
Effect of Bcl-2 overexpression on m[Ca 2+ ]
It has been shown that a tight coupling between SR Ca 2+ release channels (IP 3 Rs and ryanodine receptors) and mitochondrial Ca 2+ uptake sites operates in various types of cells [32] . CChinduced m [Ca 2+ ] increases were measured with aequorin targeted to mitochondria. As shown in Figure 5, Figures 6A and 6C) . Moreover, when the IP 3 R inhibitor 2-APB (75 µM) was perfused together with STS, the Ca 2+ spike frequency decreased approx. 1.5-fold ( Figures 6A and 6C ). This suggests that the increased Ca 2+ spike frequency is due to Ca 2+ release through IP 3 Rs. In Bcl-2-overexpressing myotubes, nearplasma membrane Ca 2+ spike frequency was only increased 2.5-fold in the presence of STS ( Figures 6B and 6C) , which is consistent with Bcl-2 overexpression inhibiting Ca 2+ spikes triggered by STS. The addition of the IP 3 R inhibitor xestospongin D did not further increase the inhibition already triggered by Bcl-2 overexpression. Moreover, Ca 2+ spike frequency in Bcl-2-overexpressing dystrophic myotubes was similar to that recorded in dystrophic myotubes perfused with 2-APB but which do not overexpress Bcl-2. Altogether, these results show that STS increases near-plasma membrane Ca 2+ spike frequency in dystrophic myotubes and that overexpression of Bcl-2 counteracts the effect of STS. Moreover, near-plasma membrane Ca 2+ spike frequencies are reduced in myotubes by Bcl-2 or by 2-APB, suggesting that the decrease in Ca 2+ spike frequency may be dependent on reduction of IP 3 R-dependent Ca 2+ release.
Effect of Bcl-2 overexpression on cell survival and apoptosis
We next investigated the effect of Bcl-2 overexpression on cell survival. In addition to STS, we used H 2 O 2 , which induces reactive oxygen species formation in similar cultures [35] . Control C57 and dystrophic myotubes were exposed for 18 h to H 2 O 2 (1 mM) or STS (0.1 µM) followed by cell survival assay using acid phosphatase activity. As shown in Figure 7 , both compounds decreased cell survival of control C57 and mdx myotubes. Figure 7B ). In contrast, cell survival of control C57 myotubes was not affected by Bcl-2 overexpression ( Figure 7A ). When myotubes were treated with H 2 O 2 , Bcl-2 overexpression had no effect on cell survival in both cell types ( Figures 7A and 7B) . It is therefore likely that Bcl-2 overexpression protects only dystrophic myotubes against cell death triggered by STS. As acid phosphatase measurement does not discriminate between necrosis and apoptosis, we used a specific apoptosis assay. When myotubes were treated with STS, 28.35 + − 3.30 % of the control C57 cells and 59.91 + − 2.56 % of the dystrophic cells were apoptotic ( Figure 8A ), confirming the fact that dystrophic myotubes are more sensitive to STS than control C57 cells. When Bcl-2 was overexpressed in these myotubes, the number of apoptotic cells decreased in dystrophic cells only (from 59.91 + − 2.56 to 45.55 + − 3.35 %), showing that Bcl-2 overexpression does not protect control C57 myotubes. When cells were treated with H 2 O 2 , Bcl-2 overexpression did not change the apoptotic rate significantly in both control C57 and dystrophic myotubes ( Figure 8B ). These results show that Bcl-2 overexpression counteracts the STS-induced apoptosis in dystrophic myotubes only and that H 2 O 2 -induced apoptosis remains unchanged in Bcl-2-overexpressing myotubes.
IP 3 sponge protects dystrophic myotubes from STS-induced apoptosis
Dystrophic myotubes were transfected with a plasmid containing either Bcl-2 or the IP 3 sponge. IP 3 sponge has been shown to behave as a very specific IP 3 chelator and to inhibit IP 3 -mediated Ca 2+ responses [25] . After 3-4 days of differentiation, cells were treated with STS (0.1 µM) for 18 h. As shown above (Figure 8A ), Bcl-2 decreased STS-induced apoptosis in dystrophic myotubes. More interestingly, apoptosis was also decreased from 59.91 + − 2.56 to 39.09 + − 1.32 % in myotubes transfected with the IP 3 sponge (Figure 9 ). The decrease observed in Bcl-2-overexpressing myotubes was not statistically different from the value obtained with the IP 3 sponge. This result strongly suggests that the IP 3 pathway is involved in STS-induced apoptosis in dystrophic myotubes.
DISCUSSION
In these experiments we have investigated the effect of Bcl-2 overexpression on Ca 2+ homoeostasis and apoptosis in both control C57 and dystrophic myotubes. Plasma membrane-and mitochondrial-targeted aequorin fusion proteins have been used to study the effect of Bcl-2 overexpression on pm [Ca 2+ ] and m[Ca 2+ ] following nAChR stimulation of both types of myotubes.
First, we found that CCh-induced near-plasma membrane Ca 2+ responses are 4.5 times higher in dystrophic myotubes compared with control C57 cells, indicating that exaggerated near-plasma membrane Ca 2+ responses occur in dystrophic myotubes during physiological activation. These results are in agreement with previous reports on dystrophic myotubes and fibres showing that a subsarcolemmal Ca 2+ overload occurs in these cells [23, 36] . Secondly, we show here for the first time that Bcl-2 overexpression counteracts the elevated Ca 2+ transients upon physiological activation. On the other hand, Bcl-2 overexpression had no effect in control C57 myotubes, indicating that overexpressed Bcl-2 protein reduces CCh-induced near-plasma membrane Ca 2+ responses in dystrophic myotubes by a mechanism that is present or visible only in these cells. We have previously shown that . Plain columns represent dystrophic myotubes that were not transfected with Bcl-2. Hatched columns represent Bcl-2-overexpressing dystrophic myotubes. *, ** and *** correspond to a significant decrease (P < 0.05, 0.01 < P < 0.001 and P < 0.001 respectively) using Student's t test. xesto D, xestospongin D.
Ca
2+ release mechanisms are different between control C57 and dystrophic myotubes [21] as proposed in other cell types [18] . Indeed, it has been shown that Bcl-2 protein interacts allosterically with the C-terminal part of the channel and in this way decreases its open probability [18] . Our results indicate that such an inhibition may operate in our dystrophic myotubes as IP 3 -induced near-plasma membrane Ca 2+ responses were reduced by Bcl-2 overexpression. However, Bcl-2 overexpression has also been shown to reduce SR Ca 2+ content in some cell types [16] . In our experiments, such an effect of Bcl-2 overexpression on SR Ca 2+ content is unlikely, as the amount of releasable Ca 2+ from the SR (estimated using caffeine-induced near-plasma membrane Ca 2+ responses) was not significantly different in dystrophic myotubes overexpressing Bcl-2 or not. Our results therefore suggest that the Bcl-2 protein, when overexpressed in dystrophic myotubes, is likely to inhibit IP 3 Rdependent Ca 2+ release and possibly subsequent IP 3 R-dependent SOCC-dependent influx after CCh stimulation.
We also found that CCh induced mitochondrial Ca 2+ increases in both control C57 and dystrophic myotubes, suggesting that mitochondrial Ca 2+ uptake sites are closely linked to SR in our myotubes, as demonstrated in other cell types [32] . Moreover, we show that CCh-induced mitochondrial Ca 2+ responses are 1.5 times higher in dystrophic myotubes as compared with control C57 cells, indicating that transient mitochondrial Ca 2+ overload occurred during nicotinic activation of dystrophic myotubes, similar to what was observed by Robert et al. [23] during highpotassium stimulations. In both control C57 and dystrophic Histogram showing the effects of Bcl-2 overexpression and IP 3 sponge on apoptosis induced by STS in dystrophic myotubes. The bar graphs correspond to mean apoptosis rate + − S.E.M.; n 15; *** corresponds to a significant decrease (P < 0.001) using one-way ANOVA followed by a Dunnett post-hoc test when compared with the control bar. The Bcl-2 bar and IP 3 sponge bar were not significantly different (using Student's t test). 2+ increases were not affected by Bcl-2 overexpression. Bcl-2 proteins, when overexpressed in these control C57 myotubes, are likely to act on mitochondria by a direct mechanism such as inhibition of cytochrome c release [40] or by decreasing Ca 2+ influx into mitochondria through the Ca 2+ uniporter [41] , which is consistent with the co-localization of Bcl-2 and mitochondria observed in our myotubes. Ca 2+ overload is known to play a key role in apoptosis by activating a cascade of proteolytic enzymes [42] . In particular, mitochondrial Ca 2+ overload can induce PTP opening, resulting in the release of pro-apoptotic factors such as cytochrome c [40] . Moreover, cytochrome c has been shown to bind to IP 3 R and to induce Ca 2+ release from the endoplasmic reticulum, amplifying Ca 2+ -dependent apoptosis [43] . As Bcl-2 overexpression counteracted transient near-plasma membrane and mitochondrial Ca 2+ overload, we have investigated the effect of Bcl-2 overexpression on cell survival and apoptosis in our myotubes. When myotubes were exposed to two types of stress, both control C57 and dystrophic myotubes displayed increased apoptosis and decreased cell survival. However, dystrophic myotubes were more sensitive to H 2 O 2 -and STS-induced stresses. These results are in agreement with previous studies indicating that dystrophin-deficient cells are more susceptible to free radicals [35] . However, Bcl-2 overexpression was unable to protect both control C57 and dystrophic myotubes against reactive oxygen species produced by H 2 O 2 . On the other hand, Bcl-2 overexpression decreased STS-induced apoptosis selectively in dystrophic myotubes. As STS increased the frequency of near-plasma membrane Ca 2+ spikes in dystrophic myotubes, our results suggest that STS is likely to trigger Ca 2+ -dependent apoptosis, as shown previously [34] . Recently, it was proposed that once apoptosis is induced by STS in HeLa cells, caspase 3 can remove the IP 3 -binding site and most of the regulatory domain of type 1 IP 3 R, thus triggering formation of a 'channel only' domain that remains constitutively open and which leads to Ca 2+ leak in the cytosol [44] . Our results show that both an IP 3 R inhibitor (2-APB) and Bcl-2 overexpression reduced the STS effect on Ca 2+ spike frequency, which suggests that leaky IP 3 R may be involved in Ca 2+ spikes and subsequent Ca 2+ overload triggered by STS. Overall, our results suggest that the anti-apoptotic effect of Bcl-2 may be explained by its inhibitory effect on STS-triggered Ca overload, possibly by a direct inhibition of IP 3 R [18] . Moreover, the fact that the transiently transfected IP 3 sponge inhibited STSdependent apoptosis indicates that the IP 3 pathway is involved in this form of cell death. Overexpressed Bcl-2 proteins may therefore exert their anti-apoptotic effect by inhibiting IP 3 Rs, which are overexpressed in dystrophic myotubes [20] and could lead to abnormal Ca 2+ homoeostasis near the plasma membrane (Ca 2+ leak) and in mitochondria.
To conclude, our results indicate that Bcl-2 overexpression reduces both near-plasma membrane and mitochondrial Ca 2+ responses occurring during nicotinic activation of dystrophic myotubes, most probably by inhibiting IP 3 R. Our results also indicate that Bcl-2 overexpression can prevent STS-induced apoptosis selectively in dystrophic myotubes, presumably by reducing nearplasma membrane Ca 2+ overload. As the IP 3 pathway is involved in CCh-induced Ca 2+ transients and in STS-induced apoptosis, the beneficial effect of Bcl-2 overexpression in dystrophic myotubes may be explained by a direct inhibition of IP 3 Rs, which are indeed involved in abnormal Ca 2+ homoeostasis in these cells. Thus overexpression of Bcl-2 or other anti-apoptotic proteins could represent an interesting approach to prevent muscle damage occurring in DMD.
